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The capsular polysaccharide and type 1 fimbriae are two of the major surface-located virulence properties
associated with the pathogenesis of Klebsiella pneumoniae. The capsule is an elaborate polysaccharide matrix
that encases the entire cell surface and provides resistance against many host defense mechanisms. In contrast,
type 1 fimbriae are thin adhesive thread-like surface organelles that can extend beyond the capsular matrix and
mediate D-mannose-sensitive adhesion to host epithelial cells. These fimbriae are archetypical and consist of
a major building block protein (FimA) that comprises the bulk of the organelle and a tip-located adhesin
(FimH). It is assumed that the extended major-subunit protein structure permits the FimH adhesin to function
independently of the presence of a capsule. In this study, we have employed a defined set of K. pneumoniae
capsulated and noncapsulated strains to show that the function of type 1 fimbriae is actually impeded by the
concomitant expression of a polysaccharide capsule. Capsule expression had significant effects on two param-
eters commonly used to define FimH function, namely, yeast cell agglutination and biofilm formation. Our data
suggest that this effect is not due to transcriptional/translational changes in fimbrial gene/protein expression
but rather the result of direct physical interference. This was further demonstrated by the fact that we could
restore fimbrial function by inhibiting capsule synthesis. It remains to be determined whether the expression
of these very different surface components occurs simply via random events of phase variation or in a
coordinated manner in response to specific environmental cues.
Klebsiella spp. account for up to 8% of all nosocomial infec-
tions in the Western world, placing them among the eight most
infectious agents in hospitals (35). The most important species
in the genus is Klebsiella pneumoniae, an opportunistic patho-
gen that is commonly associated with hospital-acquired urinary
tract infections (UTI), pneumonia, septicemia, and wound in-
fections. As far as nosocomial UTI is concerned, K. pneu-
moniae is second only to Escherichia coli as the major causative
agent and accounts for 6 to 17% of all infections. These infec-
tions are often linked to the use of catheters, indicating that
bacterial adhesion and biofilm formation are important for the
establishment of the infection. Of particular concern is the
recent rapid and extensive spread of antibiotic-resistant strains
(particularly against -lactam antibiotics), highlighting the
need to gain a better understanding of the mechanisms by
which this organism causes disease.
K. pneumoniae bacteria are commonly found in both clinical
and nonclinical settings. Their nonclinical habitats encompass
the gastrointestinal tracts of mammals, as well as environmen-
tal sources, such as soil, surface waters, and plants (4). Several
recent studies have shown that environmental isolates are in-
distinguishable from human clinical isolates with respect to
biochemical and virulence properties (32, 49). K. pneumoniae
produces a number of virulence factors that contribute to
pathogenesis, including fimbrial adhesins, siderophores, O an-
tigens, and capsular antigens. The capsule is considered to be
the dominant virulence property and consists of an elaborate
layer of surface-associated polysaccharides, the composition of
which is very much strain dependent. In K. pneumoniae, at least
77 distinct polysaccharides (designated the K antigens) have
been reported (29, 35). Capsule polysaccharides contribute to
pathogenesis by mediating resistance to phagocytosis and kill-
ing by serum (34, 55). Additional functions include protection
against desiccation and attack from phages. Almost all mem-
bers of the Enterobacteriaceae are able to produce a capsule,
and this property has been strongly associated with extraintes-
tinal infections, such as septicemia, meningitis, and UTI (20,
30, 33, 52). Strains causing UTI, meningitis, and sepsis are
generally also resistant to the bactericidal action of human
serum.
Another group of virulence factors produced by K. pneu-
moniae are fimbrial adhesins, protein structures that recognize
a wide range of molecular motifs and provide targeting of the
bacteria to specific tissue surfaces in the host (19). K. pneu-
moniae produces two major types of fimbriae, type 1 fimbriae
and type 3 (Mrk) fimbriae (14). Type 1 fimbriae are thin, rigid,
adhesive surface organelles found on virtually all members of
the Enterobacteriaceae (19). On a fimbriated bacterium, several
hundred of these organelles radiate peritrichously from the
surface to a distance of about 1 m. These fimbriae have been
most extensively studied in E. coli; however, the corresponding
structures of K. pneumoniae are highly similar with regard to
genetic composition and regulation (14). Type 1 fimbriae exert
their adhesive properties by virtue of the FimH adhesin, a
minor organelle component located at the tips of the fimbriae
(5). The FimH adhesin recognizes mannose-containing glyco-
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proteins that are present on many mammalian host tissues,
such as the surface of the urinary tract. This enables the bac-
teria to target, attach to, and eventually colonize the uroepi-
thelium (6, 25, 27). Type 1 fimbriation has been correlated with
urovirulence (6). Expression of type 1 fimbriae is phase vari-
able due to a flip-flop-type control system based on an invert-
ible DNA switch located immediately upstream of the major-
subunit gene. A promoter located in the switch drives the
expression of the fim genes (28). On or off orientation of the
switch results in a fimbriated or bald phenotype, respectively.
Two tyrosine class recombinases, encoded by fimB and fimE,
catalyze the inversion of the switch (18), with FimB having a
preference for off-to-on switching and FimE having a prefer-
ence for on-to-off switching (13). Type 3 fimbriae are 2- to
4-nm-wide and 0.5- to 2-m-long structural organelles pre-
dominantly composed of a major-subunit protein (MrkA) in
addition to an adhesin (MrkD) (2). They mediate attachment
to the basolateral surfaces of tracheal epithelial cells and to
components of basement membranes (51).
The capsule and fimbriae are prominent structural compo-
nents of the K. pneumoniae cell surface and play important
roles in its survival and pathogenicity. However, there are
conflicting reports in the literature regarding their simulta-
neous expression by K. pneumoniae. In a primary investigation,
Tarkkanen et al. reported that 29 of 32 encapsulated UTI K.
pneumoniae strains were capable of expressing type 1 fimbriae
(52). Conversely, Matatov et al. (26) identified an inverse re-
lationship between capsule and type 1 fimbria expression. They
screened a panel of strains derived from sepsis and UTI
sources and showed that the encapsulated sepsis isolates did
not produce type 1 fimbriae, while the majority of UTI isolates
expressed type 1 fimbriae but were noncapsulated (26). In
addition, data were presented which indicated that the encap-
sulated strains were unable to assemble functional fimbriae
(26). A study by Sahly et al. (40) partially backed the latter
findings, inasmuch as they reported that none of their capsu-
lated stains produced noticeable type 1 fimbriae. Against this
background, we have investigated possible interference be-
tween type 1 fimbriae and capsule.
MATERIALS AND METHODS
Bacterial strains and growth conditions. In this study, we primarily used K.
pneumoniae strain C105 and its noncapsulated derivative C105NCV (26, 50). A
second capsulated-noncapsulated strain pair [264(1) and 264(1)NCV] was also
employed. K. pneumoniae strain 264(1) is of serotype O7:K67 (10). A noncap-
sulated version, 264(1)NCV, was isolated essentially as previously described (46)
and does not react with anti-K67 serum. E. coli MS428 is a fim mutant of E. coli
K-12 strain MG1655 (38). E. coli MC1061 (New England BioLabs) was used for
all intermediate cloning work. Cells were grown at 37°C on solid or in liquid
Luria-Bertani (LB) medium supplemented with the appropriate antibiotics un-
less otherwise stated.
DNA manipulations. Isolation of plasmid DNA was carried out using the
QIAprep Spin Miniprep kit (QIAGEN). Restriction endonucleases were used
according to the manufacturer’s specifications (New England BioLabs). PCRs
were done as previously described (48). Amplified products were sequenced to
ensure fidelity of the PCR using the ABI PRISM BigDye Terminator cycle-
sequencing ready-reaction kit (PE Applied Biosystems). Samples were run on a
Perkin-Elmer ABI PRISM 310 Genetic Analyzer (PE Applied Biosystems) as
described in the manufacturer’s specifications.
Plasmid constructions. The FimB expression plasmid pJKS60 was constructed
as follows. The fimB gene was amplified by PCR from E. coli K-12 strain
MG1655 using the primers ms17 (5-GCGCGCCATGGAGAATAAGGCTGA
TAAC) and ms18 (5-GGGCCAAGCTTCTATAAAACAGCGTGACG) con-
taining NcoI and HindIII sites, respectively. The resulting PCR product was
digested with NcoI and HindIII and inserted into the NcoI/HindIII site of the
pBAD/myc-HisA plasmid (15) to produce plasmid pJKS60. In this construct,
expression of the fimB gene is under the control of the arabinose-inducible
araBAD promoter. The construct was sequenced to ensure fidelity of the PCR.
Blotting. Whole-cell lysates were subjected to sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis and transferred to polyvinylidene difluoride micro-
porous membrane filters as described previously (48). Western blotting was
performed using polyclonal antiserum against purified type 1 fimbriae of E. coli
K-12. Receptor blots to detect FimH were carried out essentially as described
previously (43) using -D-mannose coupled to bovine serum albumin (BSA) as
the primary reagent. Specific -D-mannose binding was visualized by incubating
the filter with anti-BSA rabbit serum and subsequently with horseradish perox-
idase-conjugated anti-rabbit immunoglobulin serum. Tetramethylbenzidine was
used as the substrate.
Agglutination of yeast cells. The capacity of bacteria to express a D-mannose-
binding phenotype was assayed by their ability to agglutinate yeast (Saccharo-
myces cerevisiae) cells on glass slides. Bacterial cells were mixed with yeast cells
(5%), and the time until agglutination occurred was measured.
Switch orientation assay. Samples were taken at regular intervals during the
fimB induction assay and placed immediately on ice. After all samples were
collected, they were centrifuged, and the cells were resuspended in 100 l H2O.
The cells were lysed by boiling them for 5 min, and 1 l of this suspension was
used as template DNA to PCR amplify the fim switch. PCR was performed with
primers 414 (5-CGTTTCGCTGGCATCTGGGAAAG) and 415 (5-AATGCA
CGGTCCCGCCGTTGACC) using the following program: 1 cycle of 94°C for 2
min; 25 cycles of 94°C for 15 s, 20°C for 30 s, 72°C for 30 s; 1 cycle of 72°C for
7 min. The products were purified, cut with BsaBI, and separated on a 2%
Tris-borate-EDTA gel.
Biofilm assay. Biofilm formation on plastic surfaces was monitored in 96-well
polystyrene microtiter plates essentially as previously described (41, 45). Briefly,
cells were grown under hydrodynamic conditions for 24 h in LB medium (con-
taining 0.2% arabinose where appropriate) at 37°C, washed to remove unbound
cells, and stained with crystal violet. Quantification of bound cells was performed
by addition of acetone-ethanol (20:80) and measurement of the dissolved crystal
violet at an optical density of 600 nm.
TEM. Cells for transmission electron microscopy (TEM) were prepared from
freshly grown colonies. Bacterial ultrastructure was examined by TEM as previ-
ously described with minor modifications (31). A Formvar-coated carbon-rein-
forced copper grid (400 mesh) was applied, film side down, on a droplet of a thick
bacterial suspension on a paraffin strip. The grid was dried on filter paper and
stained for 20 s on droplets of 1% phosphotungstic acid, and excess liquid was
sucked off with filter paper. Electron microscopy was carried out using a Philips
Morgagni D 268 electron microscope at 80 kV.
RESULTS
Expression of type 1 fimbriae is affected by the presence of
a capsule in K. pneumoniae. The vast majority of K. pneu-
moniae cells express a pronounced polysaccharide capsule.
However, noncapsulated variants (NCVs) arise spontaneously.
An isogenic pair of K. pneumoniae strain C105, differing only in
the ability to express K35 capsule antigen, was recently char-
acterized (50). To examine whether fimbria expression is af-
fected by the concomitant expression of a capsule, we trans-
formed the C105/C105NCV pair with the high-copy-number
plasmid pPKL4, which harbors the fim gene cluster from E. coli
K-12. A classical assay for monitoring type 1 fimbria-mediated
adhesion to eukaryotic cells is agglutination of yeast cells.
When overnight cultures of the two strains were compared, we
observed that the noncapsulated variant produced a rapid ag-
glutination of yeast cells (5 s) while the capsulated strain ag-
glutinated yeast cells in approximately double the time (10 to
12 s). In order to probe whether this phenomenon applied to
other K. pneumoniae strains, we employed another isogenic K.
pneumoniae wild-type/NCV pair, i.e., 264(1)/264(1)NCV, dif-
fering only in the ability to express K67 capsule. When strains
264(1) and 264(1)NCV were transformed with plasmid pPKL4
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and the resultant transformants were tested for yeast aggluti-
nation, the noncapsulated version agglutinated considerably
faster than the parent. This result was seen in repeated anal-
yses of overnight cultures and prompted us to examine the
effect in more detail.
The presence of a capsule delays the ability to detect type 1
fimbria expression. In E. coli, type 1 fimbria expression is
phase variable and controlled by two recombinases (18). The
FimB recombinase efficiently promotes off-to-on switching,
while the FimE recombinase primarily promotes on-to-off
switching (13, 18). K. pneumoniae and E. coli contain virtually
identical chromosomally encoded fim gene clusters with simi-
lar regulatory mechanisms (14, 18, 37). In order to devise a
mechanism by which we could control expression of the K.
pneumoniae type 1 fimbria genes, we cloned the E. coli fimB
gene behind the arabinose-inducible Para promoter (plasmid
pJKS60). This plasmid was then transformed into the K. pneu-
moniae C105/C105NCV isogenic strains. The strains were
grown to mid-exponential phase, induced with arabinose, and
tested for type 1 fimbria expression by yeast agglutination (Fig.
1). Fimbria expression was first detected in the noncapsulated
variant 45 min after arabinose induction, and within 110 min,
rapid agglutination (10 s) was observed. In contrast, the cap-
sulated C105 strain did not produce detectable agglutination
until 75 min after induction and maintained a significantly
slower agglutination profile throughout the course of the ex-
periment.
Capsule expression does not affect switching of the fim pro-
moter. One explanation for the above-mentioned results is that
capsule expression affects fimbria expression at the transcrip-
tional level, i.e., switching of the fim promoter (either directly
or indirectly). To explore this possibility, we examined the
orientation of the chromosomally encoded fim switch at se-
lected time points during the arabinose induction experiment
described above. In this assay, the fim switch region is PCR
amplified and then digested with BsaBI restriction endonucle-
ase, which cuts asymmetrically within the switch. The off-spe-
cific products are 204 bp and 446 bp in size, while the on-
specific products are 322 bp and 328 bp. We observed that in
both strains the first detectable “on” fragments appeared 15
min after induction with arabinose (Fig. 2). No significant
difference in “on” and “off” fragments was observed within the
course of the experiment when relative time points were com-
pared. The apparent diminution of the off products in accor-
dance with fimB induction in C105(pJKS60) may be due to
subtle variations in the PCR. However, when Fig. 1 and Fig. 2
are compared, there appears to be a 30-min lag phase between
the start of transcription and functional presentation of the
fimbrial organelle at the cell surface (noncapsulated strain),
with a further lag phase of 30 min required for penetration of
the capsule (capsulated strain). Taken together, the results
suggest that capsule expression per se does not affect switching
of the fim promoter. Also, although K. pneumoniae has a
switch sequence that is virtually identical to that of E. coli, it
has not been demonstrated previously to be invertible. We
have now shown this to be the case.
Capsule expression does not affect the amount of fimbriae
produced. Another explanation for the effect of capsule ex-
pression on fimbrial function could be that the amount of
fimbriae present at the cell surface is reduced in capsulated
strains. To examine this possibility, we employed a combina-
tion of Western and receptor blotting and electron microscopy.
The C105/C105NCV strains (containing pPKL4 for fim expres-
sion) were assessed for production of the type 1 fimbrial ad-
hesin (FimH) by Western blotting employing type 1 fimbrial
antisera aginst whole-cell lysates (Fig. 3A). The FimH protein
was found to be produced in similar amounts in both strains.
The same result was obtained using a receptor blot employing
-D-mannosylated BSA (Fig. 3B). We also examined the
strains for the production of type 1 fimbriae by transmission
electron microscopy (Fig. 4). No difference was observed in the
amounts of fimbriae observed at the surfaces of the capsulated
and noncapsulated cells, indicating that capsule expression
does not affect the synthesis or assembly of type 1 fimbriae.
Taken together, the results indicate that the most likely mech-
FIG. 1. Yeast cell agglutination profile of K. pneumoniae strains C105 (grey bars) and C105NCV (black bars) after induction of FimB
expression. Bacterial cells were mixed with a 5% suspension of yeast cells on a glass slide, and the time until agglutination occurred was recorded.
The assay is a direct measurement of functional FimH expression. The growth rates of the two strains during the course of the experiment were
identical. Data from a single experiment are presented; the experiment was repeated three times, and the results were essentially the same.
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anism by which capsule expression effects type 1 fimbrial func-
tion is physical interference.
Inhibition of capsule synthesis enhances type 1 fimbrial
function. Bacterial capsule expression can be inhibited by sev-
eral agents, including salicylate and bismuth (8). In a recent
study, bismuth-2,3-dimercaptopropanol (BisBAL) was shown
to reduce K. pneumoniae O1:K2 capsule expression by approx-
imately 90% in defined medium (9). To directly demonstrate
that the presence of a capsule on the bacterial surface inter-
feres with fimbrial function, we grew the capsulated K. pneu-
moniae C105 strain containing the inducible FimB recombi-
nase in LB medium with and without BisBAL. Consistent with
our previous data, the inhibition of capsule synthesis by the
addition of subinhibitory concentrations of BisBAL resulted in
a twofold increase in the speed of yeast cell agglutination (data
not shown).
Capsule expression hinders fimbria-mediated biofilm for-
mation. We and others have previously demonstrated that type
1 fimbriae confer excellent biofilm-forming properties upon E.
coli (36, 41, 44, 45). Although it seems reasonable to assume
that K. pneumoniae type 1 fimbriae possess similar functional
properties, such studies have not been reported previously.
Furthermore, our encapsulated-nonencapsulated strain set
provides a unique background in which to test for capsule-
mediated interference of this property. To perform these ex-
periments, the C105/C105NCV strains were transformed with
our fimB expression plasmid (pJKS60) or a vector control
(pBADMyc-HisA) and investigated for the ability to form bio-
films on an abiotic surface (in this case, polystyrene microtiter
plates) (Fig. 5). Our results show that (i) type 1 fimbriae from
K. pneumoniae can promote biofilm formation on abiotic sur-
faces, (ii) this property is blocked by the concomitant expres-
FIG. 2. In vitro recombination assay for monitoring of the influence of the capsule on FimB-mediated switching. (A) Map of the phase switch
region in both on and off orientations. Indicated are the positions of the primers used in the PCR amplification and the sizes of the DNA fragments
resulting from BsaBI digestion. IRL, inverted repeat left; IRR, inverted repeat right. (B) Acrylamide gel electrophoresis showing the amounts of
on and off DNA fragments obtained after BsaBI digestion. Samples were taken at regular time intervals after induction of FimB expression, and
the switch orientation was monitored. On fragments (204 and 446) and off fragments (322 and 328) are indicated. A DNA size marker (100 bp
to 1,200 bp, increasing by regular 100-bp increments) is shown in the middle of the gel.
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sion of a capsule, (iii) the capsule actually reduces bacterial
adhesion to such surfaces, and (iv) the expression of type 1
fimbriae may interfere with other adhesion mechanisms of K.
pneumoniae. We attribute the last observation to fimbrial
shielding of shorter adhesins as previously observed in E. coli
(16). The physical shielding of short nonfimbrial adhesins by
the capsule has also been demonstrated (42). Taken together,
the results provide further evidence that capsule expression
physically interferes with the function of type 1 fimbriae.
DISCUSSION
Bacteria express a number of surface structures that enable
them to interact with and survive in changing environments,
e.g., flagella in order to swim and adhesins in order to attach.
These surface components have highly diverse structures, and
it must be implicit that they physically interfere with each other
in such a way that the activity of one may sometimes be ob-
structed by the presence of another. As an example, we have
previously demonstrated that both fimbriae and the capsule
physically block the action of the much shorter Ag43 adhesin in
bacteria (16, 42). Such surface structure interference must
have important consequences for the interplay of bacteria with
the environment. Here, we have studied the interference be-
tween the capsule and type 1 fimbriae. The capsule is a thick
polysaccharide matrix that surrounds the entire cell, provides
resistance against host predation, and is associated with the
later developmental stages of complex biofilm structures that
display enhanced resistance to antibiotics. Fimbriae are also
required for the formation of biofilms, but predominantly dur-
ing the initial adhesion phase. Intriguingly, although the long
polymorphic structure of fimbriae allows them to penetrate the
capsule, their adhesive properties are actually impeded by its
presence, suggesting that the expression of these two major
surface components may be controlled in a coordinated man-
ner.
The capsule and type 1 fimbriae are two of the most prom-
inent virulence factors of K. pneumoniae (11, 24, 33, 54). Cap-
sular polysaccharides are produced by the majority of uro-
pathogenic Klebsiella strains and play a significant role in the
murine UTI model. A recent study reported that isogenic
capsulated and unencapsulated Klebsiella strains display signif-
icant differences in binding to human cell lines, suggesting that
the capsule might mask the activities of other surface-located
adhesins (50). The capsule shielding effect has also been dem-
onstrated in adherence studies with other organisms, including
E. coli (39, 42), Neisseria meningitides (53), and Haemophilus
influenzae (47). In this study, we have demonstrated by several
means that the function of type 1 fimbriae is also affected by
the presence of a capsule on the bacterial cell surface. First, the
capacity of type 1 fimbriae to mediate yeast cell agglutination
(a measure of function) was significantly different in the iso-
genic C105 and C105 NCV strains. Second, induction of func-
tional fimbrial expression via overexpression of the FimB re-
combinase was slower in the capsulated strain. Finally, fimbrial
function could be enhanced by the addition of capsule-inhibi-
tory substances.
In a previous study of selected K. pneumoniae UTI isolates,
it was reported that capsule formation prevents the assembly of
functional type 1 fimbriae on the bacterial surface (26). The
authors suggested that capsule expression most likely inter-
feres at the level of fimbrial assembly in the outer membrane.
Our data show that capsule expression does not effect inver-
sion of the switch-located fim promoter. However unlike the
previous study, we did not observe that the presence of a
capsule prevents the formation of type 1 fimbrial organelles at
the cell surface. Indeed, fimbrial expression was observed in
both capsulated and noncapsulated strain backgrounds. Fur-
thermore, the number of fimbriae visualized on the capsulated
strain was similar to that of the noncapsulated strain. We
therefore hypothesize that the capsule-mediated effect on fim-
brial function is most likely due to physical interference be-
tween these two very different surface structures. In light of the
fact that fimbriae on the surface of a cell can vary considerably
in length (0.1 to 2.0 m) and our electron micrographs show
that the capsule extends 0.3 to 0.5 m out from the cell surface,
there seems to be ample room for physical interference. There
are a number of mechanisms by which capsule could interfere
with fimbrial function: (i) the fimbriae (specifically FimH) may
be masked by capsular material, (ii) FimH adhesin molecules
that penetrate the capsule may be coated by the polysaccharide
and thus rendered nonfunctional, (iii) the presence of a cap-
sule may result in structural weak points within the fimbrial
organelle that induce breakage, and (iv) the presence of a
capsule may retard the flexibility of fimbriae that is required to
achieve optimal adhesion to multiple receptors on the same
target cell. An additional mechanism of functional interference
relates to the precise location of FimH in the fimbrial struc-
ture. FimH is thought to be located on the tip of the fimbrial
organelle as an integral part of a short fibril structure (17). A
FIG. 3. Western blot (A) and receptor blot (B) of total whole-cell
lysates of recombinant cells reacted with either type 1 fimbrial antisera
or -D-mannosylated BSA, respectively. Lanes 1, C105 containing
pPKL4; lanes 2, C105NCV containing pPKL4; lanes 3, MS428 con-
taining pPKL4 (positive control); lanes 4, MS428 containing pBR322
(negative control). The FimH protein is indicated. Equal amounts of
FimH were detected in both capsulated and noncapsulated K. pneu-
moniae cells (lanes 1 and 2).
4630 SCHEMBRI ET AL. INFECT. IMMUN.
 o
n
 O
ctober 20, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
model of fimbrial biosynthesis supports this view (5). However,
several independent studies have additionally suggested that
FimH is interspersed along the fimbrial shaft (1, 22). Incorpo-
ration of FimH at such points in the organelle structure would
also be consistent with the reduced level of yeast agglutination
observed in the capsulated strain, since they would be masked
by the extended polysaccharide matrix.
The regulation of capsule gene expression is complex, with
overlapping regulatory circuits. Capsule expression has been
reported to be phase variable in several organisms, including
Bacteroides fragilis (21), Neisseria meningitidis (7), and Campy-
lobacter (3). In K. pneumoniae, capsule production is influ-
enced by environmental conditions (12). Arguably, differential
expression of capsules would intermittently result in a noncap-
sulated state in which fimbriae can function at optimal effi-
ciency. At present, it is hard to say whether bacteria actually
coordinate the production of capsules and fimbriae. A recent
report suggests that the binding of type 1 fimbriae to D-man-
nose receptors triggers the down-regulation of the capsule
assembly region 1 operon in uropathogenic E. coli (46). Alter-
FIG. 4. Transmission electron micrographs of K. pneumoniae strains expressing different combinations of capsule and type 1 fimbriae. (A) C105
(capsule); (B) C105 plus pPKL4 (capsule fimbriae); (C) C105NCV (capsule); (D) C105NCV plus pPKL4 (capsule fimbriae). Scanning of
multiple cells by TEM did not reveal any significant differences in the numbers of fimbriae between C105 and C105NCV (A versus C) or between
C105(pPKL4) and C105NCV(pPKL4) (B versus D).
FIG. 5. Biofilm formation by the capsule-producing K. pneumoniae
strain C105 containing either pJKS60 (FimB) or pBAD/Myc-HisA
(control) and the capsule-negative strain C105NCV containing either
pJKS60 (FimB) or pBAD/Myc-HisA (control). FimB-promoted type
1 fimbria expression promoted an enhanced biofilm formation pheno-
type only in the absence of any capsular material. The strains were
grown under hydrodynamic conditions in LB media containing 0.2%
arabinose on polystyrene microtiter plates. Adhered cells were stained
with 0.1% crystal violet, and the absorbance was measured at 600 nm.
Shown are the averages of readings from three experiments (plus
standard deviations).
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natively, since both fimbriae and capsule expression are phase
variable, random switching between the two surface structures
may be sufficient to ensure that a percentage of the population
has an appropriate phenotype. It is also possible that bacteria
actually compromise the function of fimbriae for the advantage
conferred by the presence of a capsule in some environmental
scenarios.
The controlled induction of the FimB recombinase enabled
us to monitor the kinetics of fimbrial appearance in the cap-
sulated and noncapsulated strains. The two strain types could
be directly compared, since there was no difference in FimB-
mediated conversion of the switch-located promoter from the
“off” to the “on” state. In the C105NCV noncapsulated strain,
a lag period of approximately 30 min was observed between the
change to “on” orientation of the switch and the detection of
functional surface-located fimbriae. This time period is consis-
tent with previous reports (23, 56). Of particular relevance to
this study, however, was the fact that an additional 30-min
period elapsed before the synthesized fimbriae could penetrate
the capsule in sufficient quantities to be detected in a func-
tional form. Furthermore, this functional difference was main-
tained (albeit to a lesser extent) after extended growth of the
induced strains.
An important aspect of this study was the finding that cap-
sulation interfered with but did not abolish the function of type
1 fimbriae. These organelles have been comprehensively stud-
ied and are representative of an entire class of structurally
similar adhesins, all of which protrude approximately 1 m
from the bacterial surface. Examples include the P, S, and F1C
fimbriae of uropathogenic Escherichia coli (19). The implica-
tions of these findings are far ranging, because they mean that
the functions of these other fimbrial types may also be affected
by the presence of a capsule. Most strains of K. pneumoniae
and E. coli that cause UTI produce a capsule. In line with our
data, several other studies have actually reported that capsu-
lated bacteria adhere poorly to epithelial cells and exhibit
severe reduction in the ability to invade compared to their
noncapsulated counterparts (26, 40). The FimH adhesin has
also been shown to mediate invasion of human bladder epi-
thelial cells (25). Based on the results of this study, one might
suspect that this phenotype could be hampered by the concom-
itant expression of a capsule.
Type 1 fimbriae promote bacterial adhesion, invasion, and
biofilm formation, all of which are traits closely associated with
bacterial virulence. Capsulation protects bacteria that live in
close association with a mammalian host against several de-
fense mechanisms. Together, the two surface components play
a significant role in biofilm formation, with most models pre-
dicting that they are expressed at different phases, fimbriae for
initial adhesion and capsular polysaccharides during the devel-
opment of mature biofilm structures. The future challenge is to
decipher how bacteria orchestrate the expression of these two
important types of surface structures in order to make use of
their full survival and virulence capabilities.
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